Key result
Insulin treatment in type 2 diabetics post-myocardial infarction was associated with increased risk of non-fatal MI and stroke, whereas metformin was protective.
Why the study?
Does the choice of glucose lowering treatment (metformin, sulphonylureas, or insulin) affect cardiovascular mortality and non-fatal cardiovascular events in patients with type 2 diabetes and recent myocardial infarction?
Observational (n=1,181)
Does the choice of glucose lowering treatment (metformin, sulphonylureas, or insulin) affect cardiovascular mortality and non-fatal cardiovascular events in patients with type 2 diabetes and recent myocardial infarction?
In a post hoc analysis of post-MI patients with type 2 diabetes, metformin was associated with a reduced risk of non-fatal MI and stroke, while insulin was associated with an increased risk, highlighting the need for randomized trials to confirm these findings.
Answers are grounded in this paper and cite their sources.
Caution against altering therapy based on observational data alone; leaves open whether metformin or insulin affects post-MI cardiovascular events in type 2 diabetes.
AIMS: To explore the impact of glucose lowering treatment on prognosis in diabetic patients with myocardial infarction. METHODS AND RESULTS: 1181 type 2 diabetic patients (mean age 68 years; 67% males) discharged after myocardial infarction were followed (median of 2.1 years). At discharge, 436 patients (37%) had oral glucose lowering agents whereof 268 sulphonylureas and 200 metformin, while 690 patients (58%) were on insulin. The impact of treatment was analysed by an updated Cox proportional hazards regression model, correcting for confounders. Cardiovascular mortality was not influenced by metformin [Hazard ratio (HR) 0.93, 95% CI 0.60-1.43; P = 0.73], sulphonylureas (HR 1.15, 95% CI 0.80-1.64; P = 0.45), or insulin (HR 1.05, 95% CI 0.75-1.46; P = 0.77). The risk for non-fatal myocardial infarction and stroke increased significantly in patients on insulin (HR 1.73, 95% CI 1.26-2.37; P = 0.0007), whereas this risk was lower among those on metformin (HR 0.63, CI 0.42-0.95; P = 0.03) and unchanged with sulphonylureas (HR 0.81, 95% CI 0.57-1.14; P = 0.23). This finding remained analysing only patients with newly instituted insulin and those randomly allocated to newly instituted insulin. CONCLUSION: Controlling for confounders including glycemic control, there was no significant difference in mortality between sulphonylureas, metformin, and insulin. In this post hoc analysis, the risk of non-fatal myocardial infarction and stroke increased significantly by insulin treatment while metformin was protective. It is emphasized that this observation is done in an epidemiological analysis and should encourage to further confirmation in randomized trials.
No takes yet. Share an insight, caveat, or question.
Mellbin et al. (2007) conducted an observational in Type 2 diabetes and myocardial infarction (n=1,181). Insulin was evaluated on Cardiovascular mortality (HR 1.05, 95% CI 0.75-1.46, p=0.77). Insulin treatment in type 2 diabetics post-myocardial infarction was associated with increased risk of non-fatal MI and stroke, whereas metformin was protective.
Synapse has enriched 10 related papers. Consider them for comparative context: